Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Paxmedica Inc. is a biopharmaceutical company developing anti-purinergic drug therapies for neurological and neurodevelopmental disorders, including autism spectrum disorder, Fragile X syndromes, and chronic fatigue syndrome. Its lead candidate, PAX-101 (intravenous suramin), targets core symptoms and infectious diseases like African sleeping sickness. The company focuses on innovative drug delivery, clinical trials, and intellectual property to address unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated about 1 year ago.